These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 21080210

  • 21. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
    Rai A, Surolia A, Panda D.
    PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents.
    Cao D, Han X, Wang G, Yang Z, Peng F, Ma L, Zhang R, Ye H, Tang M, Wu W, Lei K, Wen J, Chen J, Qiu J, Liang X, Ran Y, Sang Y, Xiang M, Peng A, Chen L.
    Eur J Med Chem; 2013 Apr; 62():579-89. PubMed ID: 23425970
    [Abstract] [Full Text] [Related]

  • 23. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 24. NMK-TD-100, a novel microtubule modulating agent, blocks mitosis and induces apoptosis in HeLa cells by binding to tubulin.
    Bhattacharya S, Kumar NM, Ganguli A, Tantak MP, Kumar D, Chakrabarti G.
    PLoS One; 2013 Feb; 8(10):e76286. PubMed ID: 24116100
    [Abstract] [Full Text] [Related]

  • 25. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D, Qiu Z, Yao W, Liu Y, Huang H, Liao S, Luo Q, Xie L, Lin Z.
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [Abstract] [Full Text] [Related]

  • 26. Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.
    Wang J, Pan X, Song Y, Liu J, Ma F, Wang P, Liu Y, Zhao L, Kang D, Hu L.
    J Med Chem; 2021 Apr 22; 64(8):4870-4890. PubMed ID: 33797247
    [Abstract] [Full Text] [Related]

  • 27. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
    Yuan X, Chen Y, Zhang W, He J, Lei L, Tang M, Liu J, Li M, Dou C, Yang T, Yang L, Yang S, Wei Y, Peng A, Niu T, Xiang M, Ye H, Chen L.
    J Med Chem; 2019 Apr 25; 62(8):4158-4173. PubMed ID: 30939008
    [Abstract] [Full Text] [Related]

  • 28. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
    Wang G, Li C, He L, Lei K, Wang F, Pu Y, Yang Z, Cao D, Ma L, Chen J, Sang Y, Liang X, Xiang M, Peng A, Wei Y, Chen L.
    Bioorg Med Chem; 2014 Apr 01; 22(7):2060-79. PubMed ID: 24629450
    [Abstract] [Full Text] [Related]

  • 29. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
    Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R.
    Radiat Oncol; 2012 Sep 11; 7():154. PubMed ID: 22967802
    [Abstract] [Full Text] [Related]

  • 30. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
    Cao D, Liu Y, Yan W, Wang C, Bai P, Wang T, Tang M, Wang X, Yang Z, Ma B, Ma L, Lei L, Wang F, Xu B, Zhou Y, Yang T, Chen L.
    J Med Chem; 2016 Jun 23; 59(12):5721-39. PubMed ID: 27213819
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and evaluation of new 2-chloro-4-aminopyrimidine and 2,6-dimethyl-4-aminopyrimidine derivatives as tubulin polymerization inhibitors.
    Xu S, An B, Li Y, Luo X, Li X, Jia X.
    Bioorg Med Chem Lett; 2018 Jun 01; 28(10):1769-1775. PubMed ID: 29673981
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.
    Cancer Lett; 2013 May 10; 332(1):74-82. PubMed ID: 23348694
    [Abstract] [Full Text] [Related]

  • 34. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
    Ezelarab HAA, Ali TFS, Abbas SH, Sayed AM, Beshr EAM, Hassan HA.
    Mol Divers; 2024 Apr 10; 28(2):563-580. PubMed ID: 36790582
    [Abstract] [Full Text] [Related]

  • 35. Discovery of Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Antimultidrug Resistance Efficacy.
    Jiang F, Yu M, Liang Y, Ding K, Wang Y.
    J Med Chem; 2024 Jul 25; 67(14):12118-12142. PubMed ID: 38996194
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
    Yan J, Zhuang Q, Li Z, Xiong Y, He M, Kang C, Zhang Q, Han L, Liang E, Liu H, Ke P, Huang X.
    Eur J Pharmacol; 2021 May 05; 898():173975. PubMed ID: 33647258
    [Abstract] [Full Text] [Related]

  • 38. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M, Su Y, Wang Z, Du D, Wei S, Liao Z, Zhang Q, Zhao L, Zhang X, Han L, Jiang J, Zhan M, Sun L, Yuan S, Zhou Z.
    Biochem Pharmacol; 2021 Aug 05; 190():114641. PubMed ID: 34077738
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.